Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 5Gemcitabine 4Specimen Handling 3Nivolumab 3Drug Therapy 3epacadostat 2Therapeutics 2Taxes 2Sirolimus 2Paclitaxel 2Doxorubicin 2Blood Specimen Collection 2Biopsy 2Azacitidine 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1toripalimab 1temsirolimus 1tanespimycin 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1pegfilgrastim 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × ciforadenant × Lymphoid × Clear all
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡